ClinicalTrials.gg
Enrolling by invitationNCT06807177Updated Jan 14, 2026

Can Blood Biomarkers of Inflammation and BDNF be Used to Assess the Effectiveness of Collagen Mesotherapy in Chronic CMPS?

An observational study in Myofascial Pain Syndrome - Neck, Spondyloarthrosis and Neck Pain, sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland. Enrolling by invitation at 1 site in Poland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Spondylarthritis with a site in Poland — 2 open to participants now, 2 under way, none of them phase 3. Spondylarthritis · Poland.

Started
2025
the only one that year
Observational
3 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland

Among the 12 studies in Spondylarthritis with a site in Poland, this one is the only one that started in 2025, is one of 3 observational ones, and was the 12th registered.

Spondylarthritis

203 studies on the registry are indexed under Spondylarthritis; 52 are open to participants now.

Browse Spondylarthritis studies →

Open to participants now

2 of the 12 studies in Spondylarthritis with a site in Poland are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 37 Spondylarthritis studies recruiting now, 20 (54%) set no upper age limit and 9 (24%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Spondylarthritis with a site in Poland, or all of them as a file.
02

Study summary

The aim of the study is to assess the concentration of anti-inflammatory markers after the use of cervical spine mesotherapy in the course of pain syndrome. The study is randomized. Patients will be divided into two groups: A - mesotherapy using injectable type I collagen, B - mesotherapy using 1% lignocaine. The mesotherapy procedure will be performed five times, at weekly intervals. Blood will be collected before the start of mesotherapy, a week after its completion and after 3 months of follow-up. In addition, the effectiveness and safety of mesotherapy of the cervical spine will be assessed.

Read the detailed description

Study aim:

The main objective of this article was to answer the question: Can biomarkers of inflammatory processes in the blood and BDNF be used to evaluate the effectiveness of collagen mesotherapy in chronic CMPS? The second objective of this article is to evaluate the safety of collagen mesotherapy in chronic CMPS.

Material and methods:

The study was conducted on patients aged 18 to 80 years, of both sexes, with local, chronic cervical spine pain syndrome, without radiation of symptoms to the upper limb. The study subjects were recruited at the National Institute of Geriatric, Rheumatology and Rehabilitation in Warsaw. Patients will be recruited according to the inclusion and exclusion criteria. The study is randomized. Patients will be divided into two groups: A - mesotherapy using injectable type I collagen, B - mesotherapy using 1% lignocaine.

Each patient will have blood collected before starting mesotherapy (on the same day) to determine anti-inflammatory markers (TNF-alpha, interleukin-1-beta, interleukin-6) and BDNF. Again, a week after the end of mesotherapy (five treatments) and after 6-week of follow-up, blood will be collected to determine the same markers.

In addition, the effectiveness and safety of mesotherapy of the cervical spine will be assessed. A Numeric Rating Scale (VAS) and the Neck Disability Index (NDI) scale will be used.

03

Conditions studied

  • Myofascial Pain Syndrome - Neck
  • Spondyloarthrosis
  • Neck Pain
  • Cervical Pain

Keywords

  • mesotherapy
  • tnf alpha
  • interleukin 6
  • collagen type I
  • lignocaine
  • interleukin 1-beta
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with chronic cervical spine pain, of a muscular, myofascial and overload nature, will be qualified for the study and undergo spinal mesotherapy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with chronic (>12 weeks) cervical spine pain syndrome of muscular, myofascial nature without radiation to the upper limb
  • recent MRI or CT scan of the cervical spine (up to 6 months)
  • no serious diseases: cancer, rheumatology, metabolic
  • no allergy to lignocaine 1% or injectable type I collagen

Exclusion criteria

Exclusion Criteria:

  • another cause of cervical spine pain
  • lack of patient consent
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Injection type I collagen
  • Injection 1% lignocaine
06

What researchers measure

Primary outcomes

  1. Concentration of anti-inflammatory markers

    Blood collection before starting the mesotherapy treatment (on the same day), one week after its completion, and after 6 weeks follow-up

    Time frame: Blood collection before starting the mesotherapy treatment (on the same day), one week after its completion (after 5 weeks from start), and after 6 weeks from end

07

Study locations

1 site
  • National Institute of Geriatric, Rheumatology and Rehabilitation
    Warsaw, 02-637, Poland
08

References and documents

Publications

  • Koszela K, Paradowska-Gorycka A, Kwiatkowska B, Woldanska-Okonska M, Stypinska B, Ejma-Multanski A, Gasik R. Blood biomarkers of inflammation and brain-derived neurotrophic factor can not be used to assess the effectiveness of collagen mesotherapy in chronic cervical myofascial pain syndrome. A pilot single-blind randomized study. Rheumatol Int. 2026 Mar 2;46(3):56. doi: 10.1007/s00296-026-06094-4. PubMed 41770355 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Sep 2025, 8 months.

Of 51 observational studies under Spondylarthritis, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 201. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 4, 2025
StartActual
Jan 8, 2025
Primary completionActual
Sep 15, 2025
CompletionEst.
Jan 12, 2026
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06807177
Lead sponsor
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Jan 8, 2025
Primary completion
Sep 15, 2025
Completion
Jan 12, 2026 (estimated)
Last update
Jan 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion